European cardiology最新文献

{"title":"Erratum: Causal Characteristics of Immune Cells Associated with Aortic Dissection: A Mendelian Randomisation Analysis.","authors":"Tian-le Li, Mao-Long Fu, Li-Hong Wang, Jian-Long Wang, Ying-Wu Liu, Lei Huang","doi":"10.15420/ecr.2024.44.co1","DOIUrl":"https://doi.org/10.15420/ecr.2024.44.co1","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.15420/ecr.2024.44.].</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e15"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of the Net Clinical Benefit of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis of Randomised Controlled Trials.","authors":"Ton Duy Mai, Tri Huynh Quang Ho, Sy Van Hoang, Hoai Thi Thu Nguyen, Jeyaraj Pandian, Tan Van Nguyen, Khoa Tien Vu, Giang Song Tran, Viet Phuong Dao, Minh Cong Tran, Hung Manh Pham","doi":"10.15420/ecr.2025.07","DOIUrl":"10.15420/ecr.2025.07","url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) are the standard treatment for stroke prevention in AF. However, high-quality head-to-head comparisons of DOACs are lacking. This study compared oral anticoagulants in patients with AF.</p><p><strong>Methods: </strong>Data were retrieved from eligible randomised controlled trials (RCTs). Interventions were ranked using the surface under the cumulative ranking curve (SUCRA) and the frequentist random effects model was applied. Efficacy outcomes included stroke, systemic embolism, MI, and all-cause mortality; the safety outcome was major bleeding. A composite outcome of efficacy and net clinical benefit was also evaluated.</p><p><strong>Results: </strong>From 23,152 records, 11 eligible RCTs were identified and included in the study. Rivaroxaban was superior to vitamin K antagonists (VKA) in net clinical benefit (RR 0.75; 95% CI [0.59-0.94]; p=0.0133), but there were no significant differences between other DOACs and VKA or among the DOACs themselves. Rivaroxaban reduced the risk of the composite outcome of efficacy compared with dabigatran (RR 0.85; 95% CI [0.75-0.98]; p=0.02) and edoxaban (RR 0.84; 95% CI [0.75-0.95]; p=0.0051), but not apixaban (RR 0.89; 95% CI [0.89-1.02]; p=0.087). All DOACs showed superiority over VKA in efficacy, without an increased risk of major bleeding. Based on the SUCRA, rivaroxaban showed a favourable risk-benefit profile compared with the other anticoagulants.</p><p><strong>Conclusion: </strong>This study showed that DOACs are superior to VKA in efficacy without increasing major bleeding risk, with rivaroxaban demonstrating the most balanced risk-benefit profile. Well-designed RCTs are needed to validate these findings.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Ischaemic Syndromes: Shifting from a Coronary-centric to a Substrate-based Nomenclature is More Accurate and Inclusive.","authors":"William E Boden, Juan Carlos Kaski, C Noel Bairey Merz, Mario Marzilli, Carl J Pepine, Filippo Crea, Raffaele De Caterina","doi":"10.15420/ecr.2025.01","DOIUrl":"https://doi.org/10.15420/ecr.2025.01","url":null,"abstract":"<p><p>This article highlights the rationale for a more accurate and inclusive classification that does not focus solely on epicardial coronary lesions as the <i>causa sine qua non</i> for angina and myocardial ischaemia in all patients but rather represents a more comprehensive classification encompassing both obstructive and non-obstructive causes. Ischaemia may be 'silent' clinically or electrocardiographically and is observed in both acute and non-acute settings, as seen in patients with diabetes and other conditions associated with microvascular dysfunction. By pivoting away from the more restrictive and overly simplistic 'vessel-based' classification that disproportionately focuses on obstructed epicardial arteries to a 'substrate-based' nomenclature inclusive of both obstructive and non-obstructive causes, 'myocardial ischaemic syndromes' will better align and unify a patient-centric approach by harmonising the full spectrum of pathophysiologic causes.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e12"},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidative Stress-related Gene Signature: A Prognostic Tool for Predicting Survival in ST-elevation MI.","authors":"Shuo-Wen Sun, Xing-Jie Wang, Ruo-Chen Yan, Lei Huang, Min Hou","doi":"10.15420/ecr.2024.58","DOIUrl":"https://doi.org/10.15420/ecr.2024.58","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify differentially expressed oxidative stress-related genes (DEOSRGs) in ST-elevation MI (STEMI) patients and examine their connection to clinical outcomes.</p><p><strong>Methods: </strong>We conducted a systematic review of Gene Expression Omnibus datasets, selecting GSE49925, GSE60993 and GSE61144 for analysis. DEOSRGs were identified using GEO2R2, overlapping across the selected datasets. Functional enrichment analysis was performed to understand the biological roles of the DEOSRGs. An optimal model was constructed using Least Absolute Shrinkage and Selection Operator penalised Cox proportional hazards regression. The clinical utility of the signature was assessed through survival analysis, receiver operating characteristic (ROC) curve and decision curve analysis. A prognostic nomogram was developed to predict survival risk, with the signature being externally validated using our own plasma samples.</p><p><strong>Results: </strong>A prognostic signature was formulated, incorporating three upregulated DEOSRGs (matrix metalloproteinase-9, arginase 1, interleukin 18 receptor accessory protein) and three clinical variables (age, serum creatinine level, Gensini score). This signature successfully stratified patients into low- and high-risk groups. Survival analysis, ROC curve analysis and decision curve analysis demonstrated the signature's robust predictive performance and clinical utility within 2 years post-disease onset. External validation confirmed significant outcome differences between the risk groups.</p><p><strong>Conclusion: </strong>This study identified DEOSRGs in STEMI patients and developed a prognostic signature integrating gene expression levels and clinical variables. While the signature showed promising predictive performance and clinical utility, the findings should be interpreted considering the limitations of small sample size and control group selection.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e11"},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: 2024 European Society of Cardiology Guidelines on Peripheral Arterial and Aortic Diseases.","authors":"Giuseppe Ferrante, Brittany A Bacallao, Francesco Gioia, Guido Del Monaco, Francesco Amata","doi":"10.15420/ecr.2024.45.co1","DOIUrl":"https://doi.org/10.15420/ecr.2024.45.co1","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.15420/ecr.2024.45.].</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e10"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Risk Reduction in Patients with Type 2 Diabetes: What Does the Cardiologist Need to Know?","authors":"Martin Berger, Nikolaus Marx, Katharina Marx-Schütt","doi":"10.15420/ecr.2024.29","DOIUrl":"https://doi.org/10.15420/ecr.2024.29","url":null,"abstract":"<p><p>Patients with diabetes are at an increased risk of cardiovascular disease (CVD), including atherosclerotic CVD and heart failure. In addition, diabetes is associated with a higher risk of developing chronic kidney disease, which is considered to be one of the strongest risk factors for CVD and mortality. To address the increased cardiovascular risk of patients with diabetes, dedicated screening strategies for CVD are necessary; conversely, screening for diabetes needs to be performed in all patients with CVD to allow timely identification. Once diabetes is diagnosed, rapid implementation of treatment with therapies to reduce cardiovascular risk on top of standard of care is necessary. This review gives an overview of contemporary therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factor XI and Atrial Fibrillation: A Mismatched Pairing?","authors":"Bianca Rocca, Hugo Ten Cate","doi":"10.15420/ecr.2024.61","DOIUrl":"https://doi.org/10.15420/ecr.2024.61","url":null,"abstract":"<p><p>Factor XI (FXI) is a liver-produced coagulation zymogen that evolutionarily originated from duplication of the gene encoding for prekallikrein. It circulates in complex with high-molecular-weight kininogen, and consists of two identical subunits that bind thrombin, FXIIa and FIX. Thus, the FXI molecule has features different from other coagulation factors. Pharmacological FXI blockade using small molecules, monoclonal antibodies and antisense oligonucleotides, has been developed, with a hypothesis of a bleeding-free, effective anticoagulation. Dose-finding Phase II trials were performed for thromboprophylaxis in orthopaedic surgery, non-valvular AF and as an add-on strategy to antiplatelet drugs in acute atherothrombosis (stroke or MI). None of those studies were powered for safety or efficacy, but rather, they were used to select the optimal dose for Phase III studies. Nevertheless, their limited results were often (over)interpreted as supporting the hypothesis of the first bleeding-free anticoagulation strategy. The failure of the Phase III OCEANIC-AF trial comparing the FXI inhibitor asundexian to the FXa inhibitor apixaban in AF obliged the scientific community to reconsider the bleeding-free hypothesis and the pathophysiology of FXI. Here, the molecular, disease-related and pharmacological features of FXI were analysed to provide possible explanation(s) and hypotheses for this (temporary) failure of FXI targeting. Specifically, the authors describe the peculiar features of the molecule in the coagulation cascade, the possible mechanisms for the bypassing of FXI activity, the clinical evidence related to FXI congenital deficiency, levels measured in pro-thrombotic settings, the pathophysiology of different thromboembolic disorders and the pharmacodynamics of FXI blockade in Phase I and II studies.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e08"},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Characteristics of Immune Cells Associated with Aortic Dissection: A Mendelian Randomisation Analysis.","authors":"Tian-le Li, Mao-Long Fu, Li-Hong Wang, Jian-Long Wang, Ying-Wu Liu, Lei Huang","doi":"10.15420/ecr.2024.44","DOIUrl":"10.15420/ecr.2024.44","url":null,"abstract":"<p><strong>Background: </strong>This study investigates the causal relationships between 731 immune cell traits and aortic dissection (AD) using Mendelian randomisation (MR). By identifying specific immune cell phenotypes contributing to AD, we explore their clinical implications for risk stratification and therapeutic interventions.</p><p><strong>Methods: </strong>A bivariate MR framework analysed the causal dynamics between immune cell attributes and AD, using genetic variants as instrumental variables. Summary statistics from a genome-wide association study for 731 immune phenotypes were obtained. Univariable MR analysis was conducted using the inverse-variance weighted method supplemented by sensitivity analyses. Horizontal pleiotropy was assessed using MR-Egger and MR pleiotropy residual sum and outlier. Significant cis-expression quantitative trait loci (eQTL) were identified via the Genotype-Tissue Expression (GTEx) database, followed by tissue-specific expression and pathway analyses.</p><p><strong>Results: </strong>Four immunophenotypes exhibited positive causal effects on AD, while one showed a negative effect. Pathogenic traits included the median fluorescence intensity of CD19 on transitional B cells, immunoglobulin D^- CD38dim B cells, CD3 on CD39⁺ CD4⁺ Treg cells, and CD3 on CD39⁺ activated Treg cells. The protective trait was the absolute count of CD86⁺ myeloid dendritic cells. Sensitivity analyses validated these associations. Pathway enrichment analysis highlighted significant arterial enrichments and key biological processes, identifying SLAMF6 and CD28 as key genes.</p><p><strong>Conclusion: </strong>This study suggests potential causal roles for specific immune cell traits in AD pathogenesis, although these findings should be interpreted with caution due to study limitations. The identified immune cell types and associated eQTL genes offer promising targets for clinical risk stratification and therapeutic interventions. Future research should focus on translating these findings into practical strategies for patient care.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial Hypertension: Reconciling European Society of Hypertension and European Society of Cardiology Guidelines.","authors":"Maria Lorenza Muiesan","doi":"10.15420/ecr.2024.56","DOIUrl":"10.15420/ecr.2024.56","url":null,"abstract":"","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology.","authors":"Massimiliano Camilli, Luca Maggio, Lorenzo Tinti, Ilaria Torre, Marcello Viscovo, Marcello Viscovo, Giulia Tamburrini, Antonella Lombardo, Daniela Maria Cardinale, Giorgio Minotti, Bianca Rocca","doi":"10.15420/ecr.2024.49","DOIUrl":"10.15420/ecr.2024.49","url":null,"abstract":"<p><p>Cardio-oncology was established with the aim of defining primary and secondary prevention approaches through surveillance and the use of tools to stratify and diminish the cardiovascular risk to cancer patients. This branch of medicine also contributes to establishing a new field in translational medicine for cardiovascular disease by focusing on the interplay between cancer and heart disease. In this first article in the new cardio-oncology section of the journal, we explore the main concepts of emerging anti-cancer therapies and their plausible cardiotoxic effects and we will describe advances and gaps in knowledge, highlighting how cardio-oncology is contributing to translational cardiology. We will speculate on the complex interplay between cancer and heart failure and discuss an emerging concept known as reverse cardio-oncology. We also present the perspective that cardio-oncology represents a promising platform area of research, allowing the discovery of novel pathways involved in cardiovascular disease through the identification of toxicities induced by targeted cancer therapies.</p>","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"20 ","pages":"e05"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}